Pyrimidines And Derivatives
Apexbio Technology LLC BAY 61-3606 732983-37-8 100mg
BAY 61-3606 (CAS 732983-37-8) is a selective orally bioavailable inhibitor of spleen tyrosine kinase (SYK) displaying an IC50 of 10 nM and a Ki of 7 5 nM for SYK by competitively binding ATP This compound shows minimal activity against other tyrosine kinases such as Src Fyn Lyn Btk and Itk at concentrations up to 4 7 M BAY 61-3606 suppresses Fc RI-mediated degranulation and mediator release in mast cells and basophils as well as Fc R-driven responses in macrophages and neutrophils In preclinical models BAY 61-3606 attenuates inflammatory cell functions and reduces allergic and asthmatic responses supporting its utility in investigating SYK-mediated signaling and inflammation
Apexbio Technology LLC BAY 61-3606 732983-37-8 5mg
BAY 61-3606 (CAS 732983-37-8) is a selective orally bioavailable inhibitor of spleen tyrosine kinase (SYK) displaying an IC50 of 10 nM and a Ki of 7 5 nM for SYK by competitively binding ATP This compound shows minimal activity against other tyrosine kinases such as Src Fyn Lyn Btk and Itk at concentrations up to 4 7 M BAY 61-3606 suppresses Fc RI-mediated degranulation and mediator release in mast cells and basophils as well as Fc R-driven responses in macrophages and neutrophils In preclinical models BAY 61-3606 attenuates inflammatory cell functions and reduces allergic and asthmatic responses supporting its utility in investigating SYK-mediated signaling and inflammation
Apexbio Technology LLC BAY 61-3606 732983-37-8 10mg
BAY 61-3606 (CAS 732983-37-8) is a selective orally bioavailable inhibitor of spleen tyrosine kinase (SYK) displaying an IC50 of 10 nM and a Ki of 7 5 nM for SYK by competitively binding ATP This compound shows minimal activity against other tyrosine kinases such as Src Fyn Lyn Btk and Itk at concentrations up to 4 7 M BAY 61-3606 suppresses Fc RI-mediated degranulation and mediator release in mast cells and basophils as well as Fc R-driven responses in macrophages and neutrophils In preclinical models BAY 61-3606 attenuates inflammatory cell functions and reduces allergic and asthmatic responses supporting its utility in investigating SYK-mediated signaling and inflammation
Apexbio Technology LLC BAY 61-3606 732983-37-8 25mg
BAY 61-3606 (CAS 732983-37-8) is a selective orally bioavailable inhibitor of spleen tyrosine kinase (SYK) displaying an IC50 of 10 nM and a Ki of 7 5 nM for SYK by competitively binding ATP This compound shows minimal activity against other tyrosine kinases such as Src Fyn Lyn Btk and Itk at concentrations up to 4 7 M BAY 61-3606 suppresses Fc RI-mediated degranulation and mediator release in mast cells and basophils as well as Fc R-driven responses in macrophages and neutrophils In preclinical models BAY 61-3606 attenuates inflammatory cell functions and reduces allergic and asthmatic responses supporting its utility in investigating SYK-mediated signaling and inflammation
Medchemexpress LLC Protac BET degrader-10 | 1957234-97-7 | 99.4% | 783.29 g/mol | C39H39ClN8O6S | 5 MG
PROTAC BET Degrader-10 is a small-molecule proteolysis-targeting chimera designed to induce degradation of BET family proteins, primarily BRD4. Reported in patent WO2017007612A1 (example 37), the compound links cereblon and BRD4 ligands and has a reported DC50 of 49 nM. Typical analytical data include CAS 1957234-97-7, molecular formula C39H39ClN8O6S, molecular weight 783.29 g/mol, and purity ~99.39%.
- Induces selective BRD4 degradation in cellular assays.
- Reported DC50 of approximately 49 nM for BRD4 degradation.
- Available as solid and as a 10 mM solution in DMSO for assay flexibility.
- High chemical purity suitable for biochemical and cellular studies.
- Applicable to PROTAC mechanism-of-action and epigenetic research.